Selected article for: "MERS cov and nucleoside analog"
Author: Jácome, Rodrigo; Campillo-Balderas, José Alberto; Ponce de León, Samuel; Becerra, Arturo; Lazcano, Antonio
Title: Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
  • Cord-id: 255ltkf7
  • Document date: 2020_6_9
    • ID: 255ltkf7
    Snippet: As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronav
    Document: As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.

    Search related documents:
    Co phrase search for related documents
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and lopinavir ritonavir protease inhibitor: 1
    • active site bind and lopinavir ritonavir: 1, 2
    • adenosine analogue and lopinavir ritonavir: 1, 2, 3
    • adenosine analogue and lopinavir ritonavir protease inhibitor: 1, 2